Isaac T. Schiefer, Ph.D.
 |
Professor Of Medicinal And Biological Chemistry
|
Area of Research
Our lab carries out research in two areas at the interface of medicinal chemistry and chemical biology:
- small molecule hit-to-lead optimization- using synthetic, bioanalytical, and bioorganic chemistry
- target identification using techniques in chemical and cellular biology
Educational Background
| Post-doctoral Fellowship in听Chemical Biology | Northwestern University, 2013 |
| Ph.D. in听Medicinal Chemistry | University of Illinois at Chicago, 2012 |
| B.S.P.S. in听Medicinal and Biological Chemistry | 兔子先生传媒文化作品, 2007 |
Scope of Practice
The research in the Schiefer lab is focused on CNS drug discovery. We are a genuine multi-disciplinary research group. Specific activities carried out in the Schiefer lab include: organic synthesis; bioanalytical characterization of efficacy in primary neurons; in vitro metabolic stability and reactivity analysis; in vivo analysis of brain:plasma ratio and pharmacokinetics (using HPLC and LC-MS-MS); analysis of pharmacodynamic markers of efficacy (via ELISA, western blot, or microscopy); and in vivo behavioral efficacy studies using murine and zebrafish models of learning, memory, and motor function.
听
Our projects can be broadly classified into two categories: 1) target identification; and 2) hit-to-lead optimization. Target identification projects focus on using techniques in chemical biology to understand the molecular targets and mechanism of action of small molecules with interesting CNS activity. Ideally the knowledge gained during target ID studies will be used to produce novel proprietary small molecules, followed by hit-to-lead optimization. Our primary long-term objective is to translate SAFE and EFFECTIVE novel small molecule therapies into the clinic to improve patient outcomes and human health.
Awards, Honors and Grants
Grants
- New Investigator Award, 鈥淒evelopment of NO Mimetic Furoxans as Novel Agents for Alzheimer's Disease Therapy鈥� (Schiefer [PI]), American Association of Colleges of Pharmacy
- NIRG-15-363739, 鈥淧K/PD study on a Prototype Attenuated NO Mimetic Furoxan鈥� (Schiefer [PI]), Alzheimer鈥檚 Association
- R01AG057598,鈥淒evelopment of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease鈥� (Schiefer [PI]), NIH-NIA
- R03DA045833, 鈥淚n Vivo Photoaffinity Labeling using Casper Zebrafish for Target Identification鈥� (Schiefer [PI]), NIH-NIDA
- R03DA045350, 鈥淗igh Throughput Approaches To Determining The Lethality Of Synthetic Psychoactive Cathinones Using Danio Rerio Larvae鈥� (Hall [PI], Schiefer [Co-I]), NIH-NIDA
- R56AG005214, 鈥淪ignal shaping via multiple allosteric sites on oligomeric muscarinic receptors鈥� (Ellis [PI], Schiefer [Co-I]), NIH-NIA
Peer review
- Journal of Medicinal Chemistry; ACS Omega; ACS Medicinal Chemistry Letters; Scientific Reports (Nature); ChemMedChem; Medicinal Research Reviews; Organic & Biomolecular Chemistry; Chemistry Central; Brain Research. Guest Editor, Journal: Nitric Oxide, Special Issue: 鈥楶harmacology & Medicinal Chemistry of Nitric Oxide鈥�
NIH Study Sections
- The Blood-Brain Barrier, Neurovascular System and CNS Therapeutics
- Small Business: Drug Discovery Involving The Nervous System (ETTN)
- Small business panel on Drug Discovery for Aging, Neuropsychiatric, and Neurologic Disorders (ETTN)
- Synthetic and Biological Chemistry A Study Section (SBCA)
Issued Patents
- Furoxans as therapies for neurodegenerative disorders. Schiefer, I.; Shah, Z.; US. Pat. No. 10590119.
- Reactive Oxygen Species-Sensitive Nitric Oxide Synthase Inhibitors for the Treatment of Ischemic Stroke. Nash, Kevin M.; Schiefer, I.; Shah, Z.; US. Pat. No. 10829441
- Novel cysteine protease inhibitors and uses. Arancio, Ottavio; Fa, Mauro; Schiefer, Isaac T.; Thatcher, Gregory; US. Pat. No. 10647709.